Kyle Jenne - 15 Jan 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Signature
By: Patrick R. O'Neil, attorney-in-fact For: Kyle Jenne
Issuer symbol
IONS
Transactions as of
15 Jan 2025
Net transactions value
$0
Form type
4
Filing time
17 Jan 2025, 19:40:43 UTC
Previous filing
06 Jan 2025
Next filing
17 Apr 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Performance Restricted Stock Units Award $0 +18,700 $0.000000 18,700 15 Jan 2025 Common Stock 18,700 $0.000000 Direct F1, F2
transaction IONS Restricted Stock Unit Award $0 +28,050 $0.000000 28,050 15 Jan 2025 Common Stock 28,050 $0.000000 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F2 The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
F3 Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F4 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F5 Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.